2877 — China Shineway Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00- HK$6.40bn
- -HK$148.08m
- CNY3.78bn
- 74
- 91
- 46
- 83
Annual income statement for China Shineway Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2,656 | 3,224 | 3,951 | 4,517 | 3,778 |
| Cost of Revenue | |||||
| Gross Profit | 1,988 | 2,410 | 2,938 | 3,394 | 2,832 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2,244 | 2,502 | 3,033 | 3,274 | 2,626 |
| Operating Profit | 412 | 721 | 918 | 1,243 | 1,152 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 395 | 720 | 917 | 1,240 | 1,146 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 295 | 557 | 723 | 970 | 840 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 295 | 557 | 723 | 970 | 840 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 295 | 557 | 723 | 970 | 840 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.621 | 0.754 | 0.957 | 1.29 | 1.12 |
| Dividends per Share |